Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Teladoc Health Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Teladoc Health Inc trades at $9.26 (market cap $1.68B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 23.7× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TDOC | |
|---|---|---|
Market Cap | $39.89B | $1.68B |
Sector | Health | Health |
52-Week High | $491.22 | $9.52 |
52-Week Low | $278.09 | $4.47 |
Enterprise Value | $38.15B | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Teladoc Health (TDOC) trades at $9.28, up 0.76% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.53B in 2025 with a net loss of $200.32M, though losses are narrowing year-over-year. Recent news highlights expansion through the Walmart partnership and ongoing cost-cutting initiatives. Valuation ratios show a P/S of 0.65 and EV/EBITDA of 9.14, suggesting potential undervaluation relative to sales.
Outlook remains cautious despite improving fundamentals; analyst consensus is mixed with 35.7% buy ratings but a $8.75 price target below current levels. Key risks include persistent net losses, competitive pressures in telehealth, and high debt levels. The stock's trajectory hinges on achieving profitability and sustaining growth amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
